Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulin G (IgG) is supported by scientific evidence for use in certain cases of pneumonia, particularly in patients with underlying immunodeficiencies. IgG is the most abundant antibody in human serum and plays a central role in the body’s immune defense against bacterial and viral pathogens. In individuals with primary or secondary immunoglobulin deficiencies (such as agammaglobulinemia, common variable immunodeficiency, or some hematologic malignancies), the lack of adequate endogenous IgG increases susceptibility to recurrent infections, including pneumonia.

Intravenous immunoglobulin (IVIG) therapy—pooled IgG derived from the plasma of healthy donors—is used as a replacement therapy in these patients. Multiple clinical studies and consensus guidelines support IVIG’s effectiveness in reducing the frequency and severity of infections, including pneumonia, in immunodeficient individuals. For example, a meta-analysis published in Clinical Immunology indicates that IVIG significantly decreases the incidence of serious bacterial infections, including pneumonia, compared to placebo in these populations.

However, IVIG is not routinely used to treat pneumonia in immunocompetent individuals, nor is it a primary treatment for acute pneumonia in the general population. Its use is reserved for specific clinical scenarios where antibody-mediated immunity is compromised. Overall, the scientific evidence supporting IgG’s use in managing pneumonia is robust but limited to defined patient groups with impaired humoral immunity.

More about immunoglobin G
More about Pneumonia

Other ingredients used for Pneumonia

Other health conditions supported by immunoglobin G

Products containing immunoglobin G

Designs For Health IgGI Shield™ 105 grams